Cremieux went from arguing against the death penalty as a teenager to becoming one of the most influential voices dissecting science online. Now with 250k+ followers on X, he’s known for exposing p-hacking, outcome switching, and selection effects that skew research.

In this conversation with Niklas, here’s what they actually talk about: why effect sizes in journals rarely match FDA data, how gene therapy’s real bottleneck is delivery not targets, and why siRNA is the most underrated modality in biotech right now.

What you’ll hear in this episode:

* The heuristics he uses to spot bad research at a glance

* Why published effect sizes are often 2–3x inflated compared to FDA data

* Selection effects that quietly shape everything from education outcomes to clinical trials

* The real bottleneck in gene therapy (delivery, not targets) and why germline bans hold back obvious wins

* How pragmatic trials and IRB reform could finally fix a broken system

* Why measles might come back and the case for vaccine mandates for kids

* The truth about longevity research: most “breakthroughs” just stop early deaths, not extend the right tail

* China’s clinical trial engine vs the slow US system

* The modality he thinks is most underpriced today: siRNA

For builders in science who care more about getting it right than playing along.

More about GUEST’S work:

* Cremieux’s X

Explore Infinita City:

* Explore the Archive: The Infinita City Times

* Visit Infinita City

* Join the Builders’ Hub on Telegram

* Follow Infinita City on X

This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.infinitacitytimes.com

Ep. 99: A Conversation with Cremieux - How to Tell Good Science from Junk, and What’s Next in US Biotech & Deregulation